What Avantea does

Avantea S.r.l. is a privately held Italian laboratory headquartered in Cremona (Via Porcellasco 7/F) that has operated since 1991 in advanced animal reproductive biotechnologies and biomedical research. The company runs two integrated divisions: (1) Assisted Reproduction Services centered on OPU-ICSI (Ovum Pick Up – Intracytoplasmic Sperm Injection) for horses, equine and bovine cloning via somatic cell nuclear transfer, cattle reproduction, and wildlife genetic rescue (notably the BioRescue northern white rhino IVF program); and (2) Biotechnology Research covering transgenic animal model generation (SOD1/ALS, Stargardt disease pig models), xenotransplantation research using alpha-Gal and Neu5Gc knockout pigs in collaboration with Edwards Lifesciences and others, and in vitro toxicity testing using embryonic stem cells. Core services include embryo cryopreservation and validated proprietary protocols refined over 20+ years.

The company operates a B2B, sales-led professional services model with three primary revenue streams: veterinary reproductive services to horse breeders, stud farms, sport horse owners, and equine veterinarians; contract research and animal model provision for biomedical research institutions and pharmaceutical/medical device companies; and cloning and genetic preservation services for elite animals. Pricing is quote-based and not publicly disclosed, consistent with the specialized, project-driven nature of the work. Distribution relies on a single Cremona laboratory facility supported by a network of over 30 partner veterinary clinics across 12+ European countries that serve as referral and sample-collection points; the company also reaches customers through industry events (e.g., KWPN Stallion Show sponsorship), scientific publications, and a multilingual website. The customer base spans horse breeders, equine veterinarians, biomedical research institutions, and wildlife conservation organizations — primarily in Europe (Italy, UK, Germany, France, Netherlands, Belgium, Ireland, Spain, Portugal, Poland, Denmark, Hungary). The company is ISO 9001:2015 certified, GDPR-compliant, and follows OPBA animal welfare guidelines; it has received research funding from the European Commission, MIUR, Regione Lombardia, and EISMEA.

Avantea commercially expanded into France in April 2026 through its acquisition of Equitechnic and signed a strategic German partnership with Paul Schockemöhle Pferdehaltung in March 2026. Leadership comprises founding members Cesare Galli (CEO and Managing Director) and Giovanna Lazzari. The company maintains a partnership with Colossal Biosciences within the BioRescue consortium for endangered species de-extinction, and in April 2026 presented its xenotransplantation work at the Italian National Transplant Network General Assembly as it seeks a position in regulated organ-transplantation value chains.

Name

Avantea

Legal name

Avantea S.r.l.

Website

https://avantea.it

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

11–50 employees

Short description

Avantea is an Italian biotechnology laboratory in Cremona providing advanced animal reproductive services — OPU-ICSI, cloning, transgenic models, and xenotransplantation research — for horse breeders, equine veterinarians, and biomedical research organizations across Europe.

Ownership category

akta.pro rank

Product category

Veterinary Reproductive Biotechnology Services

NAICS

Horses and Other Equine Production (11292)

SIC

Agricultural Prod-Livestock & Animal Specialties (200), Agricultural Services (700), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Equine Reproduction Services (Embryo Transfer, AI, Fertility Clinics) (AFAEAGAK)

akta.pro secondary industries

Embryo Transfer (ET) & IVF Services (AFAEAJAB), Cloning & Advanced Reproductive Technologies Services (AFAEAJAL), Reproduction, Breeding & Theriogenology (Large Animal/Equine) (HLAMABAG), Embryo Transfer (ET) & IVF Services (Superovulation, Flushing, Implantation) (AFACAEAB)

Keywords

• Animal reproductive biotechnology
• Equine OPU-ICSI services
• Somatic cell nuclear transfer
• Transgenic animal models
• Xenotransplantation research

Headquarters

HQ city

Cremona

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Veterinary Reproductive Services: Laboratory services for assisted equine reproduction including OPU-ICSI, embryo transfer, and semen processing for breeders and stud farms. Services are provided directly to horse owners, breeders, and veterinary practitioners seeking advanced reproductive technologies.
2. Biotechnology Research Services: Contract research services for biomedical applications including animal model development, toxicity testing, and xenotransplantation research for pharmaceutical and medical device companies.
3. Cloning and Genetic Preservation: Somatic cell nuclear transfer services for cloning horses and cattle, preserving valuable genetic material from elite or endangered animals.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Avantea operates a laboratory providing advanced animal reproductive technologies for horses and cattle, principally Ovum Pick Up combined with Intracytoplasmic Sperm Injection (OPU-ICSI), somatic cell nuclear transfer (cloning), and embryo cryopreservation. The laboratory also delivers contract biotechnology research including transgenic animal model generation for biomedical studies, xenotransplantation research using genetically modified pigs, in vitro toxicity testing, and conservation reproductive programs such as the BioRescue northern white rhino IVF initiative.

Product overview

Avantea is a leading European laboratory for advanced animal reproductive technologies and biotechnological research. The company offers two integrated divisions: (1) Assisted Reproduction Services covering equine OPU-ICSI, equine cloning, cattle reproduction, and wildlife conservation through genetic rescue; and (2) Biotechnology Research providing animal models for biomedical research, xenotransplantation studies, and toxicity testing. The core product is the OPU-ICSI equine reproduction service, supported by cloning capabilities for horses and cattle, while the biotechnology division focuses on transgenic animal models, xenotransplantation, and conservation biology through advanced reproductive technologies.

Differentiator

Problem solved

Functional benefit

Products and services

• OPU-ICSI (Ovum Pick Up - Intracytoplasmic Sperm Injection) Advanced equine reproductive technology enabling embryo production from mares in sport activity or with reduced fertility, serving breeders, stud farms, and equine veterinarians.
• Cattle Reproduction Services Assisted reproduction services for cattle including OPU-ICSI and embryo production, delivered to breeding operations and livestock producers.
• Equine and Bovine Cloning Somatic cell nuclear transfer service for cloning horses and cattle, enabling preservation of valuable genetic material and production of genetically identical animals.
• Transgenic Animal Models Development and supply of genetically modified animal models (notably pigs) for biomedical research, including SOD1/hSOD1G93A ALS models and Stargardt disease models for academic and pharmaceutical researchers.
• Xenotransplantation Research Research services on pig-to-human organ transplantation using genetically modified pigs (alpha-Gal and Neu5Gc knockouts), including heart valve bioprostheses and kidney xenotransplantation studies for medical device and transplant collaborators.
• In vitro Toxicity Testing In vitro toxicity testing services using cell-based assays and embryonic stem cells for reproductive toxicology assessment, supplied to pharmaceutical and chemical industry clients.
• Genetic Rescue for Endangered Species Assisted reproductive technology program for endangered species conservation, including northern white rhino IVF and synthetic genetic rescue techniques delivered through the BioRescue consortium.

Quantifiable outcome

• Best Scientific Research Award 2023 for BioRescue white rhino IVF project from Society for Reproduction and Fertility

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core, flagship, major and strategic.

• EquitechniccoreStrategic or Co-development Partner · 16 April 2026Avantea expanded into France through the acquisition/integration of Equitechnic into the Avantea Group, strengthening presence in the French equine reproductive services market.
• Paul Schockemöhle PferdehaltungcoreStrategic or Co-development Partner · 12 March 2026German partner facility for ICSI programs, providing local support for German-speaking markets and collaborating on reproductive technology services.
• KWPN (Koninklijk Warmbloed Paardenrijdregister Nederland)coreGTM or Marketing Partner · 27 January 2026Avantea serves as sponsor of the KWPN Stallion Show 2026, one of the world's most prestigious equine selection and breeding events, strengthening brand presence in the international breeding community.
• BioRescue ConsortiumflagshipStrategic or Co-development PartnerInternational conservation consortium for synthetic genetic rescue of the northern white rhino, using Avantea's IVF technology to produce embryos from DNA recovered from museum specimens. Avantea contributes core reproductive technology expertise.
• University of Utrecht - Veterinary FacultymajorStrategic or Co-development PartnerCollaboration with Utrecht University's Department of Farm Animal Health for joint research in reproductive biotechnology.
• Leibniz Institute for Zoo and Wildlife Research (Leibniz-IZW)majorStrategic or Co-development PartnerResearch partnership for wildlife conservation and reproductive technologies applicable to endangered species.
• University of Pavia - Dipartimento di Biologia e Biotecnologia Lazzaro SpallanzanimajorStrategic or Co-development PartnerLong-standing academic partnership for biotechnology research and development.
• Regione LombardiastrategicGTM or Marketing PartnerRegional government support for biotechnology innovation and development.
• Edwards Lifesciences LLCmajorStrategic or Co-development PartnerCollaboration on heart valve bioprostheses research including xenotransplantation applications.
• Max Delbrück Center for Molecular Medicine (MDC)majorStrategic or Co-development PartnerPartnership for molecular medicine and biomedical research applications.
• Colossal BiosciencesflagshipStrategic or Co-development PartnerPartnership within BioRescue consortium for northern white rhino de-extinction efforts, utilizing synthetic genetic rescue techniques.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Genus plc: Global animal genetics company (ABS Global, PIC) operating bovine and porcine genetic improvement at scale; a broad incumbent adjacent to Avantea through its bovine IVF/sexed semen business and customer overlap with progressive breeding operations.
• IMV Technologies: Global leader in animal reproduction equipment and consumables (insemination, embryo transfer, IVF media); a broader incumbent whose customer base and channel overlap with Avantea's veterinary clinic network and whose products underpin competing labs' workflows.
• Minitube International: German-headquartered supplier of animal reproduction biotechnologies (semen processing, AI, embryo transfer) and ET services across species; comparable as both an equipment vendor and a competing provider of assisted reproduction services.

Emerging players

• eGenesis: US biotech developing genetically engineered pig organs for human transplantation; comparable to Avantea's xenotransplantation work as an emerging player in the same transgenic pig pipeline with similar scientific overlap.
• Revivicor (United Therapeutics): Subsidiary of United Therapeutics producing genetically modified pigs for xenotransplantation; closely comparable to Avantea's xenotransplantation research program in terms of core technology (alpha-Gal knockouts, organ-source animals) though focused on human therapeutic application.
• Colossal Biosciences: US-based 'de-extinction' company partnered with Avantea in the BioRescue consortium for northern white rhino synthetic genetic rescue; comparable as an emerging player combining advanced reproductive technologies with conservation science and a direct partner.

Direct peers

• Trans Ova Genetics: US-based provider of advanced reproductive technologies for cattle and other livestock including OPU-ICSI, cloning, and embryo transfer; a direct commercial peer to Avantea in bovine reproduction services with overlapping techniques.
• Kheiron Equine: Argentina-based equine cloning and assisted reproduction laboratory offering somatic cell nuclear transfer services and advanced reproductive technologies — the closest global commercial competitor to Avantea's equine cloning and OPU-ICSI offerings.
• ST Genetics: Global bovine genetics and reproduction services company offering embryo transfer, IVF, and sexed semen; comparable to Avantea through shared core methodology in cattle IVF/ICSI and an overlapping customer base of stud operations.
• Texas A&M Equine Embryo Laboratory: Academic laboratory at Texas A&M performing OPU-ICSI, embryo cryopreservation, and equine cloning research; a direct technical peer to Avantea in advanced equine reproductive protocols and a referential benchmark for the field.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avantea